Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 16;35(5):782-791.
doi: 10.1021/acs.chemrestox.1c00417. Epub 2022 Apr 13.

Influence of Nitrite on Formation of Tobacco-Specific Nitrosamines in Electronic Cigarette Liquids and Aerosols

Affiliations

Influence of Nitrite on Formation of Tobacco-Specific Nitrosamines in Electronic Cigarette Liquids and Aerosols

Xiaohong C Jin et al. Chem Res Toxicol. .

Abstract

Tobacco-specific nitrosamine (TSNA) formation occurred during aerosol generation from select commercial cig-a-like e-cigarette products. To understand the drivers behind the potential formation of TSNAs in electronic cigarette (e-cigarette) aerosols and e-liquids, model e-liquid systems were generated in the lab to demonstrate that nitrite can react with nicotine and minor alkaloids to form TSNAs in e-liquids. In the presence of nitrite and nicotine, TSNA levels in e-liquids increased over time and the process was accelerated by elevated temperature. Additionally, TSNAs formed during aerosol generation when nitrite was present in the corresponding e-liquids. The commercial e-cigarette products that showed higher levels and formation of TSNAs were observed to contain nitrite and minor alkaloid impurities in the corresponding e-liquids. This study provides valuable information about drivers for TSNA formation in e-liquids and e-cigarette aerosols that may be applied to the evaluation and quality assurance of e-cigarette products.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
TSNA formation pathway. NO2- nitrite.
Figure 2
Figure 2
Amount of NNK (A) and NNN (B) in e-liquid 1 fortified with different concentrations of nitrite and evaluated over 12 weeks (n = 3). Over the 12-week study, NNN was not detected in the samples fortified with 2 μg/g nitrite and is not shown on the chart. Error bars not seen in lines are due to small SDs.
Figure 3
Figure 3
TSNA in the aerosols of e-liquid 1 fortified with 0, 2, and 10 μg/g nitrite (n = 3). TSNA not detected or lower than the LOQ are not shown on the chart.
Figure 4
Figure 4
TSNAs in e-liquid 2 with fortified minor alkaloids and nitrite, over 8 weeks (n = 3).
Figure 5
Figure 5
Levels of TSNAs in e-liquid 2 fortified with 0.2 μg/g nitrite and 10 μg/g of each minor alkaloid, respectively, and the corresponding aerosols (n = 3 for e-liquid and n = 4 for aerosol).
Figure 6
Figure 6
TSNA levels in the e-liquid and aerosol of commercial product B (A) and product H (B) (n = 4).

References

    1. Brunnemann K. D.; Hoffmann D. Analytical studies on tobacco-specific N-nitrosamines in tobacco and tobacco smoke. Crit. Rev. Toxicol. 1991, 21, 235–240. 10.3109/10408449109017910. - DOI - PubMed
    1. Brunnemann K. D.; Prokopczyk B.; Djordjevic M. V.; Hoffmann D. Formation and analysis of tobacco-specific N-nitrosamines. Crit. Rev. Toxicol. 1996, 26, 121–137. 10.3109/10408449609017926. - DOI - PubMed
    1. Hecht S. S.; Chen C. B.; Ohmori T.; Hoffmann D.. Comparative carcinogenicity in F344 rats of the tobacco-specific nitrosamines, N’-nitrosonornicotine and 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone Cancer Res. 1980, 40 (2), 298–302.. - PubMed
    1. Hoffmann D.; Castonguay A.; Rivenson A.; Hecht S. S. Comparative carcinogenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N’-nitrosonornicotine in Syrian golden hamsters. Cancer Res. 1981, 1981, 2386–2393. - PubMed
    1. Hecht S. S. Biochemistry, Biology, and Carcinogenicity of Tobacco-Specific N-Nitrosamines. Chem. Res. Toxicol. 1998, 11, 559–603. 10.1021/tx980005y. - DOI - PubMed